- Report of Foreign Issuer (6-K)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2011

Commission File Number: 001-34541

CHINA CORD BLOOD CORPORATION

(Translation of registrant’s name into English)

48th Floor, Bank of China Tower

1 Garden Road

Central

Hong Kong S.A.R.

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_______________.

EXPLANATORY NOTE

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or China Cord Blood Corporation’s (the “Company”) future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Report on Form 6-K is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company’s expectations are as of the date this Report on Form 6-K is filed, and the Company does not intend to update any of the forward-looking statements after the date this Report on Form 6-K is filed to confirm these statements to actual results, unless required by law.

The forward-looking statements included in this Report on Form 6-K are subject to risks, uncertainties and assumptions about the Company ’ s businesses and business environments. These statements reflect the Company ’ s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company ’ s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC; changing legislation or regulatory environments in the PRC; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in the PRC, as well as general economic conditions; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission.

This report is hereby incorporated by reference to the Registration Statement on Form F-3 (File No. 333-168873) of the Company.

Results of Operations and Financial Condition

Following this cover page are the preliminary unaudited consolidated financial results for the three months and year ended March 31, 2011 of the Company.

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31, 2010 and 2011

	March 31,		March 31,
	2010		2011
	RMB		RMB		US$
	(in thousands except share data)

ASSETS
Current assets
Cash and cash equivalents		280,835		611,387		93,366
Accounts receivable, less allowance for doubtful accounts (March 31, 2010: RMB8,016; March 31, 2011: RMB11,850)		61,349		77,402		11,820
Inventories		5,070		6,729		1,028
Prepaid expenses and other receivables		13,137		9,982		1,524
Deferred tax assets		3,443		5,373		821
Total current assets		363,834		710,873		108,559
Property, plant and equipment, net		250,491		250,348		38,231
Non-current prepayments		151,138		5,752		878
Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2010: RMB9,181; March 31, 2011: RMB28,106)		176,874		240,952		36,796
Inventories		29,637		31,600		4,826
Intangible asset, net		26,297		134,412		20,526
Available-for-sale equity securities		48,475		52,733		8,053
Other investment		-		134,363		20,519
Deferred tax assets		288		2,565		392
Total assets		1,047,034		1,563,598		238,780

LIABILITIES
Current liabilities
Bank loan		45,000		45,000		6,872
Accounts payable		5,410		5,046		771
Accrued expenses and other payables		22,475		106,731		16,299
Deferred revenue		36,074		82,319		12,571
Amounts due to related parties		2,977		360		55
Income tax payable		4,098		11,156		1,704
Total current liabilities		116,034		250,612		38,272
Deferred revenue		93,155		162,668		24,841
Other non-current liabilities		15,978		30,036		4,587
Deferred tax liabilities		2,259		26,890		4,107
Total liabilities		227,426		470,206		71,807

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31, 2010 and 2011 – (continued)

	March 31,		March 31,
	2010		2011
	RMB		RMB			US$
	(in thousands except share data)

EQUITY
Shareholders’ equity
Ordinary shares
- US$0.0001 par value, 250,000,000 shares authorized, 66,743,693 shares and 75,406,875 shares issued and outstanding as of March 31, 2010 and 2011, respectively		46		52			8
Additional paid-in capital		719,329		910,316			139,016
Accumulated other comprehensive income/(loss)		2,221		(18,580	)		(2,838	)
Retained earnings		87,290		178,993			27,334
Total shareholders’ equity		808,886		1,070,781			163,520
Noncontrolling interests		10,722		22,611			3,453
Total equity		819,608		1,093,392			166,973
Total liabilities and equity		1,047,034		1,563,598			238,780

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months and Year Ended March 31, 2010 and 2011

	Three months ended March 31,									Year ended March 31,
	2010			2011						2010			2011
	RMB			RMB			US$			RMB			RMB			US$
	(in thousands except per share)

Revenues		70,806			94,671			14,457			261,536			339,532			51,850
Direct costs		(15,115	)		(20,001	)		(3,054	)		(65,730	)		(77,376	)		(11,816	)
Gross profit		55,691			74,670			11,403			195,806			262,156			40,034
Operating expenses
Research and development		(5,816	)		(1,717	)		(262	)		(5,816	)		(6,960	)		(1,063	)
Sales and marketing		(12,553	)		(13,273	)		(2,027	)		(39,480	)		(47,583	)		(7,266	)
General and administrative		(12,421	)		(23,251	)		(3,551	)		(53,317	)		(83,794	)		(12,796	)
Total operating expenses		(30,790	)		(38,241	)		(5,840	)		(98,613	)		(138,337	)		(21,125	)
Operating income		24,901			36,429			5,563			97,193			123,819			18,909
Other income, net
Interest income		1,365			2,694			411			6,411			9,065			1,384
Interest expense		(619	)		(657	)		(100	)		(2,431	)		(2,606	)		(398	)
Exchange (loss)/gain		(1,020	)		(61	)		(9	)		(417	)		486			74
Write-off of deferred reverse capitalization costs		-			-			-			(21,566	)		-			-
Others		148			269			41			473			1,378			210
Total other (expense)/income, net		(126	)		2,245			343			(17,530	)		8,323			1,270
Income before income tax		24,775			38,674			5,906			79,663			132,142			20,179
Income tax expense		(7,199	)		(10,867	)		(1,660	)		(24,770	)		(33,929	)		(5,181	)
Net income		17,576			27,807			4,246			54,893			98,213			14,998
Income attributable to noncontrolling interests		(1,447	)		(1,548	)		(236	)		(5,369	)		(6,510	)		(994	)
Income attributable to redeemable noncontrolling interests		-			-			-			(347	)		-			-
Net income attributable to shareholders		16,129			26,259			4,010			49,177			91,703			14,004

Net income per share:
Attributable to ordinary shares
-Basic		0.24			0.35			0.05			0.82			1.31			0.20
-Diluted		0.23			0.35			0.05			0.78			1.31			0.20

Other Events

On June 10, 2011, the Company issued a press release announcing preliminary unaudited consolidated financial results for the three months and year ended March 31, 2011. A copy of the press release is attached as Exhibit 99.1.

Exhibits

Exhibit No.	Description

99.1	Press Release, dated June 10, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.